262 related articles for article (PubMed ID: 28749919)
21. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
24. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
27. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
Alghandour R; Sakr DH; Shaaban Y
Ann Hematol; 2023 Jun; 102(6):1287-1300. PubMed ID: 37129698
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
29. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
[TBL] [Abstract][Full Text] [Related]
30. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
33. Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Ding YY; Kim H; Madden K; Loftus JP; Chen GM; Allen DH; Zhang R; Xu J; Chen CH; Hu Y; Tasian SK; Tan K
Clin Cancer Res; 2021 Sep; 27(18):5109-5122. PubMed ID: 34210682
[TBL] [Abstract][Full Text] [Related]
34. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
[TBL] [Abstract][Full Text] [Related]
35. Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.
Zhang W; Kuang P; Liu T
PLoS One; 2020; 15(12):e0243657. PubMed ID: 33338050
[TBL] [Abstract][Full Text] [Related]
36. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Abdelrasoul H; Vadakumchery A; Werner M; Lenk L; Khadour A; Young M; El Ayoubi O; Vogiatzi F; Krämer M; Schmid V; Chen Z; Yousafzai Y; Cario G; Schrappe M; Müschen M; Halsey C; Mulaw MA; Schewe DM; Hobeika E; Alsadeq A; Jumaa H
Nat Commun; 2020 Jun; 11(1):3194. PubMed ID: 32581241
[TBL] [Abstract][Full Text] [Related]
37. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
Li X; Zhang J; Liu F; Liu T; Zhang R; Chen Y; Guo Y; Fang Y; Xu X; Pui CH; Zhu X
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):660-666. PubMed ID: 37301632
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
39. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
Iacobucci I; Roberts KG
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]